68 Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients

Yasemin Sanli, Oner Sanli, Duygu Has Simsek, Rathan M. Subramaniam

Research output: Contribution to journalArticle

Abstract

Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.

LanguageEnglish (US)
Pages871-880
Number of pages10
JournalNuclear Medicine Communications
Volume39
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Positron Emission Tomography Computed Tomography
human glutamate carboxypeptidase II
Therapeutics

Keywords

  • 68 Ga-PET/MRI
  • 68 Ga-PSMA PET/CT
  • high-risk prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

68 Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients. / Sanli, Yasemin; Sanli, Oner; Has Simsek, Duygu; Subramaniam, Rathan M.

In: Nuclear Medicine Communications, Vol. 39, No. 10, 01.10.2018, p. 871-880.

Research output: Contribution to journalArticle

@article{20816596b978473486140f9277940805,
title = "68 Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients",
abstract = "Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.",
keywords = "68 Ga-PET/MRI, 68 Ga-PSMA PET/CT, high-risk prostate cancer",
author = "Yasemin Sanli and Oner Sanli and {Has Simsek}, Duygu and Subramaniam, {Rathan M.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1097/MNM.0000000000000888",
language = "English (US)",
volume = "39",
pages = "871--880",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - 68 Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients

AU - Sanli, Yasemin

AU - Sanli, Oner

AU - Has Simsek, Duygu

AU - Subramaniam, Rathan M.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.

AB - Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.

KW - 68 Ga-PET/MRI

KW - 68 Ga-PSMA PET/CT

KW - high-risk prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85054234227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054234227&partnerID=8YFLogxK

U2 - 10.1097/MNM.0000000000000888

DO - 10.1097/MNM.0000000000000888

M3 - Article

VL - 39

SP - 871

EP - 880

JO - Nuclear Medicine Communications

T2 - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 10

ER -